Long-term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli-durability 24-month observational study
Diabetes, Obesity and Metabolism, cilt.27, sa.10, ss.5487-5497, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 27 Sayı: 10
- Basım Tarihi: 2025
- Doi Numarası: 10.1111/dom.16591
- Dergi Adı: Diabetes, Obesity and Metabolism
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Sayfa Sayıları: ss.5487-5497
- Anahtar Kelimeler: glycaemic control, iGlarLixi, insulin therapy, real-world evidence, type 2 diabetes
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim: To evaluate the effectiveness and safety of a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi) over 24 months in people with type 2 diabetes (T2D). Methods: In this retrospective, observational study, data were collected from the Optum Market Clarity® database in the United States. People with T2D aged ≥18 years, previously treated with oral antidiabetic drugs ± basal insulin or glucagon-like peptide-1 receptor agonists, who initiated iGlarLixi between 1 January 2017 and 31 March 2020 and received ≥1 iGlarLixi prescription were included. The primary outcome was change in HbA1c 24 months after starting iGlarLixi. Secondary outcomes included change in HbA1c from baseline, achievement of HbA1c <7%, change in body weight and rate of hypoglycaemia (defined as inpatient or outpatient claims, or blood glucose <70 mg/dL) every 3 months over 24 months. Results: In total, 1685 people were included in this analysis (mean age, 58.4 years; 52.6% female). In the overall population, including imputed values, mean ± standard deviation (SD) baseline HbA1c (9.3 ± 1.8%) was reduced by 0.9% to 8.3 ± 1.8% at 24 months. A HbA1c target of <7% was achieved in 22.2% of people at 24 months. Mean ± SD body weight remained stable from baseline (102.1 ± 24.2 kg) to 24 months (101.9 ± 23.3 kg). The hypoglycaemia event rate was 16.1 per 100 person-years (P100PY) at baseline and decreased to 11.4 P100PY at 24 months. Conclusions: iGlarLixi initiation was associated with improved glycaemic control, without body weight change or increased hypoglycaemia over 24 months.